RIL
NPCE icon

Rothschild Investment LLC’s Neuropace NPCE Stock Holding History

Rothschild Investment LLC’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$184 Buy
+14
New +$210 ﹤0.01% 3319

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Rothschild Investment LLC's NPCE Position: Q1 2026 in Review

Rothschild Investment LLC opened a new position in Neuropace (NPCE) in Q1 2026: 14 shares worth $184. The stake represents ﹤0.01% of the portfolio and ranks #3319 among its holdings.

113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • Rothschild Investment LLC held 14 shares of Neuropace worth $184 as of Q1 2026.
  • Neuropace was a new Rothschild Investment LLC position in Q1 2026.
  • Neuropace made up ﹤0.01% of Rothschild Investment LLC's portfolio in Q1 2026, its #3319 holding.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on Rothschild Investment LLC's 13F filing for Q1 2026, filed 7 May 2026.